CICON19

Immune-based treatments—known collectively as immunotherapy—have already provided remarkable benefits against cancer, including relief for people with advanced cancers that do not respond to other treatments. These…

“Checkpoint inhibition has become the hallmark of cancer immunotherapy,” declared Ton N. Schumacher, Ph.D., a member of the Cancer Research Institute (CRI) Scientific Advisory Council (SAC) from the Netherlands Cancer…

The second day of CICON19 kicked off with Johns Hopkins University’s Elizabeth M. Jaffee, M.D., one of the recipients of the 2019 William B. Coley Award, who gave the annual Coley lecture. Jaffee, a member of the CRI…

The third day of CICON19 opened with session 7 devoted to tumor antigens, with a talk by Yardena Samuels, Ph.D., of the Weizmann Institute of Science (Israel), who discussed her work covering a variety of issues relating…

Session 11: Immuno-Oncology Crosstalk and Metabolism The final day of CICON19 began with a talk by Greg M. Delgoffe, Ph.D., of the University of Pittsburgh, who focused on how metabolism influences T cell exhaustion in…